By Steve Holland
WASHINGTON (Reuters) – The U.S. Food and Drug Administration (FDA) has granted authorization to Gilead Sciences Inc (O:) for emergency use of its experimental antiviral drug remdesivir to treat patients with COVID-19, the agency and President Donald Trump said on Friday.
During a meeting in the Oval Office with Trump, Gilead Chief Executive Daniel O’Day called the move an important first step and said the company was donating 1.5 million vials of the drug to help patients.
“We’re humbled by this being an important first step for … hospitalized patients. We want to make sure nothing gets in the way of these patients getting the medicine, so we made a decision to donate about 1.5 million vials,” he said.
Gilead said on Wednesday the drug had helped improve outcomes for patients with COVID-19, the respiratory disease…